Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Toronto
$27,000.00
Lung Transplantation using Hepatitis B Positive Donors to Hepatitis B Negative Recipients using Ex-Vivo Treatment of Organs: A Safety Trial
EF 2025-26
Résumé
Lung transplantation is a life-saving treatment for patients with severe lung disease, but there is a major shortage of donated lungs. Because of this, up to 20% of patients die while waiting for transplants. One major problem is that many lungs are turned down if the donor is infected with a virus. One example is hepatitis B virus (HBV). Donors with active HBV infection are not used for transplantation, because of the high risk of passing the infection to the recipient.
The Toronto lung transplant program often uses Ex-Vivo Lung Perfusion (EVLP), which is a machine that keeps donor lungs alive outside the body and allows doctors to treat them before transplant. In a previous clinical trial, we showed that ultraviolet (UV) light during EVLP can reduce viruses in donated lungs. By shining UV light on the fluids passing through the lung, we eliminated hepatitis C virus in lungs from infected donors. Because of these promising results, we hope to use a similar strategy to remove HBV from donor lungs and make them safe for transplantation.
This study will test whether lungs from donors with active HBV can be safely transplanted after UV light treatment during EVLP and a short, 28-day course of medications against HBV. We believe that combining UV light with HBV medications will prevent the virus from spreading to recipients. We will transplant 20 patients using lungs from donors with active HBV. We will then monitor all recipients with regular blood tests for one year to check for any signs of infection. The main goal of this study is to determine whether this approach prevents HBV transmission. If successful, this strategy could allow us to use donor lungs that are currently discarded, reduce waitlist deaths, and guide similar approaches for other organs and viruses.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
572736
Name
Ferro Alejandro
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Lung Transplantation using Hepatitis B Positive Donors to Hepatitis B Negative Recipients using Ex-Vivo Treatment of Organs: A Safety Trial
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Antiviral Therapy; Evlp; Hepatitis B Virus; Lung Transplant
Abstract
Lung transplantation is a life-saving treatment for patients with severe lung disease, but there is a major shortage of donated lungs. Because of this, up to 20% of patients die while waiting for transplants. One major problem is that many lungs are turned down if the donor is infected with a virus. One example is hepatitis B virus (HBV). Donors with active HBV infection are not used for transplantation, because of the high risk of passing the infection to the recipient.
The Toronto lung transplant program often uses Ex-Vivo Lung Perfusion (EVLP), which is a machine that keeps donor lungs alive outside the body and allows doctors to treat them before transplant. In a previous clinical trial, we showed that ultraviolet (UV) light during EVLP can reduce viruses in donated lungs. By shining UV light on the fluids passing through the lung, we eliminated hepatitis C virus in lungs from infected donors. Because of these promising results, we hope to use a similar strategy to remove HBV from donor lungs and make them safe for transplantation.
This study will test whether lungs from donors with active HBV can be safely transplanted after UV light treatment during EVLP and a short, 28-day course of medications against HBV. We believe that combining UV light with HBV medications will prevent the virus from spreading to recipients. We will transplant 20 patients using lungs from donors with active HBV. We will then monitor all recipients with regular blood tests for one year to check for any signs of infection. The main goal of this study is to determine whether this approach prevents HBV transmission. If successful, this strategy could allow us to use donor lungs that are currently discarded, reduce waitlist deaths, and guide similar approaches for other organs and viruses.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ferro, Alejandro
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~